Value-based prices of emerging disease-modifying therapies for Alzheimer's disease in 174 countries: a cost-effectiveness and threshold analysis
Hoang, Men Thi ; Kahn, James G. ; Saha, Sanjib LU
and Trépel, Dominic
(2026)
In Alzheimer's & Dementia
22(5).
- Abstract
- Abstract INTRODUCTION Countries have varying, limited healthcare budgets for emerging disease-modifying therapies. Cost-effectiveness analysis, combined with country-level cost-effectiveness thresholds, can be used to estimate value-based prices (VBPs) for lecanemab and donanemab across 174 countries. METHODS The cost-effectiveness of lecanemab and donanemab was estimated using incremental cost and quality-adjusted life years (QALYs) compared to usual care. Published cost-effectiveness thresholds were used to estimate VBPs of these drugs across 174 countries. RESULTS Compared to usual care, lecanemab and donanemab respectively increased average QALYs by 0.38 and 0.51. By country income status, VBPs for lecanemab and donanemab respectively... (More)
- Abstract INTRODUCTION Countries have varying, limited healthcare budgets for emerging disease-modifying therapies. Cost-effectiveness analysis, combined with country-level cost-effectiveness thresholds, can be used to estimate value-based prices (VBPs) for lecanemab and donanemab across 174 countries. METHODS The cost-effectiveness of lecanemab and donanemab was estimated using incremental cost and quality-adjusted life years (QALYs) compared to usual care. Published cost-effectiveness thresholds were used to estimate VBPs of these drugs across 174 countries. RESULTS Compared to usual care, lecanemab and donanemab respectively increased average QALYs by 0.38 and 0.51. By country income status, VBPs for lecanemab and donanemab respectively ranged between $254 to $9434 and $387 to $13,964 (high income), $90 to $1025 and $137 to $1507 (upper middle income), $11 to $623 and $21 to $956 (lower middle income) and $4 to $18 and $9 to $32 (low income). DISCUSSION VBPs indicate how much 174 countries should be willing to pay. This framework can also be adapted and refined in the negotiation of country pricing. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/e03e82ad-cf90-49a6-8c5b-e4e335c204b9
- author
- Hoang, Men Thi
; Kahn, James G.
; Saha, Sanjib
LU
and Trépel, Dominic
- organization
- publishing date
- 2026
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, cost-effectiveness analysis, decision-analytic modeling, dementia, disease-modifying therapies, donanemab, economic evaluation, lecanemab, threshold analysis, value-based pricing
- in
- Alzheimer's & Dementia
- volume
- 22
- issue
- 5
- article number
- e71308
- publisher
- Wiley
- external identifiers
-
- pmid:42125995
- scopus:105039216537
- ISSN
- 1552-5260
- DOI
- 10.1002/alz.71308
- language
- English
- LU publication?
- yes
- id
- e03e82ad-cf90-49a6-8c5b-e4e335c204b9
- date added to LUP
- 2026-05-13 15:06:40
- date last changed
- 2026-05-25 04:00:59
@article{e03e82ad-cf90-49a6-8c5b-e4e335c204b9,
abstract = {{Abstract INTRODUCTION Countries have varying, limited healthcare budgets for emerging disease-modifying therapies. Cost-effectiveness analysis, combined with country-level cost-effectiveness thresholds, can be used to estimate value-based prices (VBPs) for lecanemab and donanemab across 174 countries. METHODS The cost-effectiveness of lecanemab and donanemab was estimated using incremental cost and quality-adjusted life years (QALYs) compared to usual care. Published cost-effectiveness thresholds were used to estimate VBPs of these drugs across 174 countries. RESULTS Compared to usual care, lecanemab and donanemab respectively increased average QALYs by 0.38 and 0.51. By country income status, VBPs for lecanemab and donanemab respectively ranged between $254 to $9434 and $387 to $13,964 (high income), $90 to $1025 and $137 to $1507 (upper middle income), $11 to $623 and $21 to $956 (lower middle income) and $4 to $18 and $9 to $32 (low income). DISCUSSION VBPs indicate how much 174 countries should be willing to pay. This framework can also be adapted and refined in the negotiation of country pricing.}},
author = {{Hoang, Men Thi and Kahn, James G. and Saha, Sanjib and Trépel, Dominic}},
issn = {{1552-5260}},
keywords = {{Alzheimer's disease; cost-effectiveness analysis; decision-analytic modeling; dementia; disease-modifying therapies; donanemab; economic evaluation; lecanemab; threshold analysis; value-based pricing}},
language = {{eng}},
number = {{5}},
publisher = {{Wiley}},
series = {{Alzheimer's & Dementia}},
title = {{Value-based prices of emerging disease-modifying therapies for Alzheimer's disease in 174 countries: a cost-effectiveness and threshold analysis}},
url = {{http://dx.doi.org/10.1002/alz.71308}},
doi = {{10.1002/alz.71308}},
volume = {{22}},
year = {{2026}},
}